6-K filed Jul 21, 2026 at 07:06 ET
Telix Pharmaceuticals reported Q2 2026 revenue of US$247M, +21% YoY and +7% QoQ, driven by Precision Medicine (+30% YoY). FY2026 revenue guidance is tracking at the upper end of US$950M-$970M, with total 2026 revenue and other income expected to exceed US$1B including a US$40M non-refundable payment from Regeneron. The company also announced a strategic collaboration with Regeneron, a US$600M convertible bond refinancing extending maturities, and FDA alignment to advance the ProstACT Phase 3 trial of TLX591-Tx.